TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 8, 2023. Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 6770 (Primary Standard Industrial Classification Code Number) 98-172573 (I.R.S. Emplo ...

Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 Table of Contents As filed with the Securities and Exchange Commission on August 24, 2023. 4225 Executive Square, Suite 600 La Jolla, CA 92037 Tel: 858-247-0520 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Dr. Someit Sidhu 4225 Executive Square, Suite 600 La Jolla, CA Tel: 1-858-247-0520 (Name, address, including zip code ...

Financial Performance - Zura Bio Limited reported a net loss of $34.0 million for the three months ended June 30, 2023, and $43.6 million for the six months ended June 30, 2023, with an accumulated deficit of $86.8 million as of June 30, 2023[134]. - The net loss for the three months ended June 30, 2023, was $34.0 million, compared to a net loss of $0.9 million for the same period in 2022, indicating a significant increase in losses[160]. - Net loss attributable to redeemable noncontrolling interest was $0.2 million for the six months ended June 30, 2023[175]. Revenue and Funding - The company has not generated any revenue from product sales and has not conducted any clinical tests since its inception[133]. - Cash and cash equivalents as of June 30, 2023, were $112.8 million, funded through various financing activities including $56.7 million from a Business Combination[178]. - Cash provided by financing activities for the six months ended June 30, 2023, was $125.4 million, primarily from the issuance of shares and warrants[193]. - The company has not generated any revenue since inception and does not expect to do so for at least the next few years[181]. Expenses and Costs - Zura Bio anticipates significant increases in expenses as it advances preclinical and clinical development, seeks regulatory approvals, and scales up manufacturing capabilities[134]. - Research and development expenses for the three months ended June 30, 2023, were $28.2 million, an increase of $28.1 million compared to $0.1 million for the same period in 2022, primarily due to a $27.2 million expense related to the acquisition of an in-process research and development ("IPR&D") license from Lilly[161]. - General and administrative expenses for the three months ended June 30, 2023, were $5.7 million, an increase of $4.8 million compared to $0.9 million for the same period in 2022, mainly due to a $3.4 million increase in compensation-related expenses[162]. - The total operating expenses for the three months ended June 30, 2023, were $33.9 million, compared to $33.0 million for the same period in 2022, reflecting an overall increase in operational costs[160]. - For the six months ended June 30, 2023, research and development expenses totaled $33.1 million, an increase of $25.5 million compared to $7.6 million for the same period in 2022, driven by the acquisition of IPR&D licenses[170]. - General and administrative expenses for the six months ended June 30, 2023, were $8.5 million, an increase of $7.3 million compared to $1.2 million for the same period in 2022, primarily due to higher compensation and professional fees[171]. - The total operating expenses for the six months ended June 30, 2023, were $41.6 million, compared to $8.7 million for the same period in 2022, reflecting a substantial increase in overall expenses[169]. Future Outlook - The company anticipates a substantial increase in research and development expenses in the foreseeable future as it continues to develop product candidates and manufacturing processes[157]. - Future operations depend on the ability to finance cash requirements for research and development and commercialization of product candidates[180]. - The company expects expenses to increase significantly as it continues research and development and seeks marketing approval for product candidates[182]. - The company may need substantial additional funding to support ongoing operations and product development[184]. Licensing and Agreements - The company entered into a license agreement with Lilly for the development of ZB-106, involving an upfront payment of $5.8 million and 1,000,000 Class A Ordinary Shares valued at $7.84 each[145]. - Zura Bio is obligated to make up to $155.0 million in development milestone payments and up to $440 million in sales milestone payments based on net sales of products developed from ZB-106[149]. - The company anticipates significant future contingent payments to Pfizer and Lilly upon achieving certain milestones, with ongoing royalties in the mid-single digits to low double-digits percentage range[183]. Company Structure and Reporting - The company qualifies as a "smaller reporting company" under the Securities Act and Exchange Act, with a market value of Class A Ordinary Shares held by non-affiliates being less than $250 million or annual revenue below $100 million[201]. - The company may continue to rely on exemptions from certain disclosure requirements as long as it remains a smaller reporting company[201]. - As a smaller reporting company, the company can present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K[201]. - The company has reduced disclosure obligations regarding executive compensation due to its status as a smaller reporting company[201]. - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[202].

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 11, 2023. Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 6770 (Primary Standard Industrial Classification Code Number) 98-172573 (I.R.S. Employe ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 21, 2023. Registration No. 333-272628 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 6770 (Primary Standard Industrial Classification Code Number) 98-172573 (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission on June 13, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZURA BIO LIMITED (Exact name of Registrant as specified in its charter) Cayman Islands 6770 98-172573 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) 4225 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40598 ZURA BIO LIMITED (Exact name of Registrant as specified in its Charter) Cayman Islands 98-1725736 (State ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number:001-40598 ZURA BIO LIMITED (Exact name of registrant as specified in its Charter) Cayman Islands NA (State or other jur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | JATT Acquisition Corp | | | | --- | --- | --- | | (Exact Name of Registrant as Specified in its Charter) | | | | Cayman Islands | 001-40598 | N/A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to JATT Acquisition Corp (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-40598 N/A (State or other jurisdiction of incorporation) ...